Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809240712> ?p ?o ?g. }
- W2809240712 endingPage "1206" @default.
- W2809240712 startingPage "1206" @default.
- W2809240712 abstract "Aggregated α-synuclein is believed to be central to the pathogenesis of Parkinson disease (PD). PRX002/RG7935 (PRX002) is a humanized monoclonal antibody designed to target aggregated forms of α-synuclein, thereby inhibiting neuron-to-neuron transfer of presumed pathogenic forms of α-synuclein, potentially resulting in neuronal protection and slowing disease progression.To evaluate the safety and tolerability of multiple intravenous infusions of PRX002 in patients with idiopathic PD.Multicenter, randomized, double-blind, placebo-controlled, multiple ascending-dose trial at 8 US study centers from July 2014 to September 2016. Eligible participants were aged 40 to 80 years with mild to moderate idiopathic PD (Hoehn and Yahr stages 1-3).Participants were enrolled into 6 ascending-dose cohorts and randomly assigned to receive PRX002 (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, 10 mg/kg, 30 mg/kg, or 60 mg/kg) or placebo. Participants received 3 intravenous infusions every 4 weeks of PRX002 or placebo and were monitored during a 24-week observational period.Safety and tolerability assessments included physical and neurological examinations, laboratory tests, vital signs, and adverse events. Pharmacokinetic parameters included maximum PRX002 concentration, area under the curve, and half-life.Of the 80 participants, most were white (97.5%; n = 78) and male (80%; n = 64); median (SD) age was 58 (8.4) years. PRX002 was generally safe and well tolerated; no serious or severe PRX002-related treatment-emergent adverse events (TEAEs) were reported. The TEAEs experienced by at least 5% of patients receiving PRX002, irrespective of relatedness to study drug, were constipation (9.1%; n = 5), infusion reaction (7.3%; n = 4), diarrhea (5.5%; n = 3), headache (5.5%; n = 3), peripheral edema (5.5%; n = 3), post-lumbar puncture syndrome (5.5%; n = 3), and upper respiratory tract infection (5.5%; n = 3). No antidrug antibodies were detected. Serum PRX002 levels increased in an approximately dose-proportional manner; mean terminal elimination half-life was similar across all doses (10.2 days). Rapid dose- and time-dependent mean reductions from baseline vs placebo in free serum α-synuclein levels of up to 97% were seen after a single infusion at the highest dose (F78,284 = 1.66; P = .002), with similar reductions after 2 additional infusions. Mean cerebrospinal fluid PRX002 concentration increased with PRX002 dose and was approximately 0.3% relative to serum across all dose cohorts.Single and multiple doses of PRX002 were generally safe and well tolerated and resulted in robust binding of peripheral α-synuclein and dose-dependent increases of PRX002 in cerebrospinal fluid, reaching cerebrospinal fluid concentrations that may be expected to engage extracellular aggregated α-synuclein in the brain. Findings support the design of an ongoing phase 2 clinical study (NCT03100149).ClinicalTrials.gov Identifier: NCT02157714." @default.
- W2809240712 created "2018-06-29" @default.
- W2809240712 creator A5011050340 @default.
- W2809240712 creator A5012189956 @default.
- W2809240712 creator A5013394867 @default.
- W2809240712 creator A5014646926 @default.
- W2809240712 creator A5015328792 @default.
- W2809240712 creator A5023026853 @default.
- W2809240712 creator A5028557857 @default.
- W2809240712 creator A5036297287 @default.
- W2809240712 creator A5037725543 @default.
- W2809240712 creator A5042490892 @default.
- W2809240712 creator A5048338049 @default.
- W2809240712 creator A5054279699 @default.
- W2809240712 creator A5060664922 @default.
- W2809240712 creator A5063444335 @default.
- W2809240712 creator A5067625175 @default.
- W2809240712 creator A5068655451 @default.
- W2809240712 creator A5072187926 @default.
- W2809240712 creator A5083620898 @default.
- W2809240712 creator A5085009648 @default.
- W2809240712 date "2018-10-01" @default.
- W2809240712 modified "2023-10-16" @default.
- W2809240712 title "Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease" @default.
- W2809240712 cites W1527671059 @default.
- W2809240712 cites W1860081569 @default.
- W2809240712 cites W1977682751 @default.
- W2809240712 cites W1991604513 @default.
- W2809240712 cites W1999214985 @default.
- W2809240712 cites W2003181166 @default.
- W2809240712 cites W2011473770 @default.
- W2809240712 cites W2025575563 @default.
- W2809240712 cites W2025922492 @default.
- W2809240712 cites W2029319167 @default.
- W2809240712 cites W2044407202 @default.
- W2809240712 cites W2050647292 @default.
- W2809240712 cites W2072053377 @default.
- W2809240712 cites W2073449985 @default.
- W2809240712 cites W2089522371 @default.
- W2809240712 cites W2097020324 @default.
- W2809240712 cites W2098069894 @default.
- W2809240712 cites W2111216320 @default.
- W2809240712 cites W2117503265 @default.
- W2809240712 cites W2131222480 @default.
- W2809240712 cites W2164627569 @default.
- W2809240712 cites W2170262356 @default.
- W2809240712 cites W2195477255 @default.
- W2809240712 cites W2203238224 @default.
- W2809240712 cites W2211989828 @default.
- W2809240712 cites W2275107578 @default.
- W2809240712 cites W2288541447 @default.
- W2809240712 cites W2309910088 @default.
- W2809240712 cites W2321620653 @default.
- W2809240712 cites W2330649365 @default.
- W2809240712 cites W2338538733 @default.
- W2809240712 cites W2436134149 @default.
- W2809240712 cites W2507685477 @default.
- W2809240712 cites W2557770353 @default.
- W2809240712 cites W2571180541 @default.
- W2809240712 cites W2578596646 @default.
- W2809240712 cites W2616646328 @default.
- W2809240712 cites W2682693068 @default.
- W2809240712 cites W2734566243 @default.
- W2809240712 cites W2778992055 @default.
- W2809240712 cites W4206067633 @default.
- W2809240712 cites W4211044101 @default.
- W2809240712 cites W4232369698 @default.
- W2809240712 cites W4235609664 @default.
- W2809240712 cites W4250035444 @default.
- W2809240712 doi "https://doi.org/10.1001/jamaneurol.2018.1487" @default.
- W2809240712 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6233845" @default.
- W2809240712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29913017" @default.
- W2809240712 hasPublicationYear "2018" @default.
- W2809240712 type Work @default.
- W2809240712 sameAs 2809240712 @default.
- W2809240712 citedByCount "200" @default.
- W2809240712 countsByYear W28092407122018 @default.
- W2809240712 countsByYear W28092407122019 @default.
- W2809240712 countsByYear W28092407122020 @default.
- W2809240712 countsByYear W28092407122021 @default.
- W2809240712 countsByYear W28092407122022 @default.
- W2809240712 countsByYear W28092407122023 @default.
- W2809240712 crossrefType "journal-article" @default.
- W2809240712 hasAuthorship W2809240712A5011050340 @default.
- W2809240712 hasAuthorship W2809240712A5012189956 @default.
- W2809240712 hasAuthorship W2809240712A5013394867 @default.
- W2809240712 hasAuthorship W2809240712A5014646926 @default.
- W2809240712 hasAuthorship W2809240712A5015328792 @default.
- W2809240712 hasAuthorship W2809240712A5023026853 @default.
- W2809240712 hasAuthorship W2809240712A5028557857 @default.
- W2809240712 hasAuthorship W2809240712A5036297287 @default.
- W2809240712 hasAuthorship W2809240712A5037725543 @default.
- W2809240712 hasAuthorship W2809240712A5042490892 @default.
- W2809240712 hasAuthorship W2809240712A5048338049 @default.
- W2809240712 hasAuthorship W2809240712A5054279699 @default.
- W2809240712 hasAuthorship W2809240712A5060664922 @default.
- W2809240712 hasAuthorship W2809240712A5063444335 @default.
- W2809240712 hasAuthorship W2809240712A5067625175 @default.